Carlos P. Nunes MD , Claudio Rodrigues MD , Mendel Suchmacher MD , Claudia Regina Esteves MD , Karin Gonçalves PhD , Hélio Rzetelna MD , Rafael V. Rodrigues MD , Luciana Regina de Vasconcelos MD , Spyros G.E. Mezitis MD, PhD , Heros Rabelo MSc , Renato Kaufmann MD, PhD , Fernanda Schwarz MChem , Henrique Goldberg (In Memoriam) MD , Aline Sintoveter MD , Mauro Geller MD, PhD
{"title":"γ -氨基丁酸、谷氨酸、钙、硫胺素、吡哆醇和氰钴胺与生姜提取物联合治疗慢性运动病的临床评价","authors":"Carlos P. Nunes MD , Claudio Rodrigues MD , Mendel Suchmacher MD , Claudia Regina Esteves MD , Karin Gonçalves PhD , Hélio Rzetelna MD , Rafael V. Rodrigues MD , Luciana Regina de Vasconcelos MD , Spyros G.E. Mezitis MD, PhD , Heros Rabelo MSc , Renato Kaufmann MD, PhD , Fernanda Schwarz MChem , Henrique Goldberg (In Memoriam) MD , Aline Sintoveter MD , Mauro Geller MD, PhD","doi":"10.1016/j.curtheres.2023.100719","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures.</p></div><div><h3>Objective</h3><p>To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (n = 170) and extract of <em>Zingiber officinale</em> (ginger) (Group B) (n = 165) in the management of chronic complaints consistent with motion sickness.</p></div><div><h3>Methods</h3><p>Both groups were tested according to the following end points, under self-paired as well as comparative study designs: reduction of ≥20 score points in the total motion sickness assessment questionnaire (MSAQ) score, percentage of patients presenting a reduction of the total MSAQ score, absolute MSAQ score reduction, physician's assessment scores, final overall assessment of study medication, and willingness to continue treatment. Safety was also evaluated.</p></div><div><h3>Results</h3><p>There was a statistically significant better performance under both study designs for Group A (<em>P</em> = 0.05 using different statistical tests) in all end points. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes.</p></div><div><h3>Conclusions</h3><p>Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and the Group A regimen was more effective than Group B.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100719"},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000280/pdfft?md5=736b3f768b0eb7b2c6a3bb1f6b818624&pid=1-s2.0-S0011393X23000280-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A Combination of Gamma-Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine, and Cyanocobalamin vs Ginger Extract in the Management of Chronic Motion Sickness: A Clinical Evaluation\",\"authors\":\"Carlos P. Nunes MD , Claudio Rodrigues MD , Mendel Suchmacher MD , Claudia Regina Esteves MD , Karin Gonçalves PhD , Hélio Rzetelna MD , Rafael V. Rodrigues MD , Luciana Regina de Vasconcelos MD , Spyros G.E. Mezitis MD, PhD , Heros Rabelo MSc , Renato Kaufmann MD, PhD , Fernanda Schwarz MChem , Henrique Goldberg (In Memoriam) MD , Aline Sintoveter MD , Mauro Geller MD, PhD\",\"doi\":\"10.1016/j.curtheres.2023.100719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures.</p></div><div><h3>Objective</h3><p>To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (n = 170) and extract of <em>Zingiber officinale</em> (ginger) (Group B) (n = 165) in the management of chronic complaints consistent with motion sickness.</p></div><div><h3>Methods</h3><p>Both groups were tested according to the following end points, under self-paired as well as comparative study designs: reduction of ≥20 score points in the total motion sickness assessment questionnaire (MSAQ) score, percentage of patients presenting a reduction of the total MSAQ score, absolute MSAQ score reduction, physician's assessment scores, final overall assessment of study medication, and willingness to continue treatment. Safety was also evaluated.</p></div><div><h3>Results</h3><p>There was a statistically significant better performance under both study designs for Group A (<em>P</em> = 0.05 using different statistical tests) in all end points. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes.</p></div><div><h3>Conclusions</h3><p>Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and the Group A regimen was more effective than Group B.</p></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"99 \",\"pages\":\"Article 100719\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0011393X23000280/pdfft?md5=736b3f768b0eb7b2c6a3bb1f6b818624&pid=1-s2.0-S0011393X23000280-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X23000280\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000280","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
A Combination of Gamma-Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine, and Cyanocobalamin vs Ginger Extract in the Management of Chronic Motion Sickness: A Clinical Evaluation
Background
Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures.
Objective
To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (n = 170) and extract of Zingiber officinale (ginger) (Group B) (n = 165) in the management of chronic complaints consistent with motion sickness.
Methods
Both groups were tested according to the following end points, under self-paired as well as comparative study designs: reduction of ≥20 score points in the total motion sickness assessment questionnaire (MSAQ) score, percentage of patients presenting a reduction of the total MSAQ score, absolute MSAQ score reduction, physician's assessment scores, final overall assessment of study medication, and willingness to continue treatment. Safety was also evaluated.
Results
There was a statistically significant better performance under both study designs for Group A (P = 0.05 using different statistical tests) in all end points. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes.
Conclusions
Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and the Group A regimen was more effective than Group B.
期刊介绍：
We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics.
CTR encourages and supports the submission of manuscripts describing:
• Interventions designed to understand or improve human health, disease treatment or disease prevention;
• Studies that focus on problems that are uncommon in resource-rich countries;
• Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing);
• Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English;
• Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
